ARJUN GOYAL - 02 Jun 2021 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role: Director
Signature: /s/ Marella Thorell, attorney-in-fact
Issuer symbol: CNTA
Transactions as of: 02 Jun 2021
Net transactions value: +$49,999,998
Form type: 4
Filing time: 04 Jun 2021, 17:00:38 UTC
Previous filing: 27 May 2021
Next filing: 06 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CNTA	Ordinary Shares	Conversion of derivative security		+3,095,909			3,095,909	02 Jun 2021	See footnote	F1, F2, F3
transaction	CNTA	Ordinary Shares	Conversion of derivative security		+85,909			85,909	02 Jun 2021	See footnote	F1, F2, F4
transaction	CNTA	Ordinary Shares	Purchase	$14,595,000	+729,750	+24%	$20.00	3,825,659	02 Jun 2021	See footnote	F1, F3
transaction	CNTA	Ordinary Shares	Purchase	$405,000	+20,250	+24%	$20.00	106,159	02 Jun 2021	See footnote	F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CNTA	Series A Preferred Shares	Award	$34,054,999	+3,095,909		$11.00	3,095,909	29 Jan 2021	Ordinary Shares	3,095,909		See footnote	F1, F2, F3, F5, F6
transaction	CNTA	Series A Preferred Shares	Award	$944,999	+85,909		$11.00	85,909	29 Jan 2021	Ordinary Shares	85,909		See footnote	F1, F2, F4, F5, F6
transaction	CNTA	Series A Preferred Shares	Conversion of derivative security	$0	-3,095,909	-100%	$0.000000^*	0	02 Jun 2021	Ordinary Shares	3,095,909		See footnote	F1, F2, F3
transaction	CNTA	Series A Preferred Shares	Conversion of derivative security	$0	-85,909	-100%	$0.000000^*	0	02 Jun 2021	Ordinary Shares	85,909		See footnote	F1, F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date.
F3	Held by Vida Ventures II, LLC ("Vida II Main Fund"). VV Manager II, LLC ("VV Manager II") is the manager of Vida II Main Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F4	Held by Vida Ventures II-A, LLC ("Vida II Parallel Fund"). VV Manager II is the manager of Vida II Parallel Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F5	This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
F6	On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital ("Share Split"). This amount has been adjusted to give effect to the Share Split.